Clinical Trials · NCT00672399
Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 70
- Start date
- Apr 2008
- Locations
- 2 sites, United Kingdom
- Primary endpoint
- Comparison of exenatide's effect on QT interval when compared to placebo